LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Home・Aandelen Lijst・Bridgebio Pharma Inc

Bridgebio Pharma Inc

Gesloten

SectorGezondheidszorg

69.17 -1.76

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

68.41

Max

69.46

Belangrijke statistieken
By Trading Economics
Inkomsten	24M -167M
Verkoop	40M 195M
EPS	-0.84
Winstmarge	-85.626
Werknemers	834
EBITDA	75M -105M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+55.16% upside

Dividenden
By Dow Jones
Volgende Winsten	4 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-581M 13B
Vorige openingsprijs	70.93
Vorige sluitingsprijs	69.17

Nieuwssentiment

By Acuity

31%

69%

84 / 345 Rangschikking in Healthcare

Bridgebio Pharma Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

25 mei 2026, 08:24 UTC

Belangrijke Marktbewegers

Acquisities, Fusies, Overnames

Uber's $11.6 Billion Takeover Approach Lifts Delivery Hero Shares

25 mei 2026, 21:22 UTC

Winsten

Disney's 'Mandalorian and Grogu' Conquers Memorial Day Weekend Box Office -- Barrons.com

25 mei 2026, 20:50 UTC

Marktinformatie

Winsten

Basic Materials Roundup: Market Talk

25 mei 2026, 16:20 UTC

Marktinformatie

Winsten

Basic Materials Roundup: Market Talk

25 mei 2026, 16:01 UTC

Marktinformatie

China's Crude Imports Pullback Helps Cap Price Upside -- Market Talk

25 mei 2026, 14:43 UTC

Marktinformatie

Oil Unlikely to Fall Significantly Until Hormuz Fully Reopens -- Market Talk

25 mei 2026, 14:15 UTC

Marktinformatie

Crude Futures Retreat As U.S.-Iran Progress Toward Deal -- Market Talk

25 mei 2026, 13:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

25 mei 2026, 12:58 UTC

Marktinformatie

Over 60% of Albertans Indicate No Interest in Separation From Canada -- Market Talk

25 mei 2026, 12:56 UTC

Marktinformatie

Winsten

Canadian Earnings Lifted by Higher Commodity Prices in Latest Quarter -- Market Talk

25 mei 2026, 12:48 UTC

Marktinformatie

Interest-Rate Cuts Unlikely in 2026 Even if Middle East Conflict Ends -- Market Talk

25 mei 2026, 12:48 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

25 mei 2026, 12:34 UTC

Marktinformatie

Dollar Extends Falls on U.S.-Iran Deal Prospects -- Market Talk

25 mei 2026, 12:10 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Delivery Hero's Assets Look Strategic -- Market Talk

25 mei 2026, 11:00 UTC

Marktinformatie

Euro, Sterling, Riskier Currencies Rise Versus Weaker Dollar -- Market Talk

25 mei 2026, 10:19 UTC

Marktinformatie

Swiss Franc Rises to Highest in More Than Two Months Vs Euro -- Market Talk

25 mei 2026, 10:05 UTC

Winsten

Tenaga Nasional: Well-Positioned to Navigate Global Geopolitical Uncertainties

25 mei 2026, 10:04 UTC

Winsten

Tenaga Nasional: Operational Performance to Remain Resilient in 2026

25 mei 2026, 10:03 UTC

Winsten

Tenaga Nasional: 1Q Operating Profit Rose on Higher Electricity Demand, Lower Fuel Prices

25 mei 2026, 10:02 UTC

Winsten

Tenaga Nasional: 1Q Rev Rose on Higher Electricity Sales

25 mei 2026, 10:01 UTC

Winsten

Tenaga Nasional 1Q Net Up 3.7% on Year

25 mei 2026, 10:00 UTC

Winsten

Tenaga Nasional 1Q Rev Up 6.6% on Year

25 mei 2026, 09:56 UTC

Winsten

Tenaga Nasional Malaysia 1st-Quarter 2026 Earnings Summary Table

25 mei 2026, 09:56 UTC

Winsten

Tenaga Nasional 1Q EPS MYR0.1883

25 mei 2026, 09:56 UTC

Winsten

Tenaga Nasional 1Q Rev MYR17.1B

25 mei 2026, 09:56 UTC

Winsten

Tenaga Nasional 1Q Net MYR1.1B

25 mei 2026, 09:38 UTC

Marktinformatie

U.S.-Iran Talks Lifted Sentiment But No Agreement Would Quickly Restore Normal Market Conditions -- Market Talk

25 mei 2026, 09:33 UTC

Marktinformatie

Global Equities Roundup: Market Talk

25 mei 2026, 09:33 UTC

Marktinformatie

India's Gold Import Tax Raise Won't Curb Demand -- Market Talk

25 mei 2026, 08:55 UTC

Marktinformatie

European Energy Stocks Slide on Falling Oil Prices -- Market Talk

Peer Vergelijking

Prijswijziging

Bridgebio Pharma Inc Prognose

Koersdoel

By TipRanks

55.16% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 107.25 USD 55.16%

Hoogste 157 USD

Laagste 82 USD

Gebaseerd op 17 Wall Street-analisten die 12-maands prijsdoelen bieden voor Bridgebio Pharma Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

17 ratings

Buy

Hold

Sell

Gebaseerd op 17 analisten die aandelenratings hebben gegeven aan Bridgebio Pharma Inc - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

84 / 345 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Bridgebio Pharma Inc

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.